Research Analysts Issue Forecasts for CRL Q3 Earnings

Key Points

• William Blair has issued Q3 2025 earnings per share (EPS) estimates for Charles River Laboratories, predicting an EPS of $2.31 for the quarter, with a consensus full-year estimate of $9.36.
• Several analysts have upgraded their ratings for Charles River Laboratories, with Jefferies Financial Group raising their target price from $142.00 to $195.00 and Citigroup from $150.00 to $200.00.
• Charles River Laboratories has a market capitalization of $7.73 billion and its stock has varied between $91.86 and $230.02 over the past year.

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Analysts at William Blair issued their Q3 2025 EPS estimates for shares of Charles River Laboratories International in a research report issued to clients and investors on Tuesday, September 16th. William Blair analyst M. Smock forecasts that the medical research company will post earnings of $2.31 per share for the quarter. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International's Q4 2025 earnings at $2.52 EPS, Q1 2026 earnings at $2.70 EPS, Q2 2026 earnings at $3.13 EPS, Q3 2026 earnings at $2.48 EPS and Q4 2026 earnings at $2.64 EPS.

Several other equities analysts have also recently issued reports on CRL. Wall Street Zen cut Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Jefferies Financial Group upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and increased their price target for the company from $142.00 to $195.00 in a research report on Tuesday, September 9th. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their price objective for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. Finally, Barclays lifted their price target on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 7th. Six research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average price target of $177.07.

Charles River Laboratories International Stock Down 0.5%

NYSE:CRL traded down $0.77 during trading hours on Friday, hitting $153.12. The stock had a trading volume of 152,478 shares, compared to its average volume of 1,213,620. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $230.02. The business has a 50 day simple moving average of $160.19 and a two-hundred day simple moving average of $148.02. The company has a market cap of $7.54 billion, a PE ratio of -115.19, a price-to-earnings-growth ratio of 4.15 and a beta of 1.47.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 EPS.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares of the company's stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On Charles River Laboratories International

Large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Charles River Laboratories International by 2.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock valued at $763,000 after purchasing an additional 105 shares during the last quarter. Rafferty Asset Management LLC grew its position in Charles River Laboratories International by 5.5% in the fourth quarter. Rafferty Asset Management LLC now owns 6,860 shares of the medical research company's stock worth $1,266,000 after acquiring an additional 360 shares in the last quarter. State of Wyoming lifted its stake in Charles River Laboratories International by 15.3% in the fourth quarter. State of Wyoming now owns 1,260 shares of the medical research company's stock worth $233,000 after purchasing an additional 167 shares during the last quarter. Tidal Investments LLC raised its stake in shares of Charles River Laboratories International by 8.8% during the fourth quarter. Tidal Investments LLC now owns 9,196 shares of the medical research company's stock valued at $1,698,000 after acquiring an additional 744 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of Charles River Laboratories International by 309.6% during the fourth quarter. Two Sigma Investments LP now owns 78,861 shares of the medical research company's stock valued at $14,558,000 after acquiring an additional 59,610 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).